Ergoteles LLC Immuno Gen, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $290,763 - $1.55 Million	77,537 New	77,537 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $70,898 - $98,322	15,582 New	15,582 $77,000
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $548,751 - $963,536	-128,815 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $410,675 - $648,435	86,458 Added 204.12%	128,815 $956,000
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $212,632 - $279,132	42,357 New	42,357 $240,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.